Preparation of 5′-O-(1-Thiotriphosphate)-Modified Oligonucleotides Using Polymerase-Endonuclease Amplification Reaction (PEAR)

Antisense oligonucleotides (ASODNs) have been widely used as an important tool for regulating gene expression, and developed into therapeutics. Natural ODNs are susceptible to nuclease degradation, nucleic acid analogues, however, have less side effects, stronger stability and more potent activities. Large-scale de novo synthesis of a certain oligonucleotide has been very difficult and costly. In a previous preliminary study, we developed the polymerase-endonuclease amplification reaction (PEAR) for amplification and large-scale preparation of natural antisense ODNs. Here we extended the method in preparation of a widely used modified oligonucleotide with 5′-O-(1-Thiotriphosphate) modifications. Using electrospray ionization liquid chromatography mass spectrometry (ESI/LC/MS) detection, the purity of the PEAR product was measured as high as 100.0%. Using PEAR a large amount of a specific oligonucleotide can be produced starting from a small amount of synthetic seeds. It is suggested that PEAR can be a useful tool for large-scale production of modified oligonucleotides.

[1]  J. Wengel,et al.  Enzymatic Incorporation of LNA Nucleotides into DNA Strands , 2007, Chembiochem : a European journal of chemical biology.

[2]  J. Wengel,et al.  Efficient enzymatic synthesis of LNA-modified DNA duplexes using KOD DNA polymerase. , 2009, Organic & biomolecular chemistry.

[3]  C. Wahlestedt,et al.  Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation , 2012, Nature Biotechnology.

[4]  J. Weiler,et al.  Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease? , 2006, Gene Therapy.

[5]  C. Cooper,et al.  CPG 7909, an Immunostimulatory TLR9 Agonist Oligodeoxynucleotide, as Adjuvant to Engerix-B® HBV Vaccine in Healthy Adults: A Double-Blind Phase I/II Study , 2004, Journal of Clinical Immunology.

[6]  Leaf Huang,et al.  Targeted intracellular delivery of antisense oligonucleotides via conjugation with small-molecule ligands. , 2010, Journal of the American Chemical Society.

[7]  D. Klinman.  Immunotherapeutic uses of CpG oligodeoxynucleotides , 2004, Nature Reviews Immunology.

[8]  K. Anderson,et al.  High-Throughput Analysis of Oligonucleotides Using Automated Electrospray Ionization Mass Spectrometry , 2004 .

[9]  S. Freier,et al.  Potent inhibition of microRNA in vivo without degradation , 2008, Nucleic acids research.

[10]  S. Kauppinen,et al.  Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus Infection , 2010, Science.

[11]  Michal Hocek,et al.  Preparation of short cytosine-modified oligonucleotides by nicking enzyme amplification reaction. , 2012, Chemical communications.

[12]  M. Stougaard,et al.  A new enzymatic route for production of long 5'-phosphorylated oligonucleotides using suicide cassettes and rolling circle DNA synthesis , 2007, BMC biotechnology.

[13]  W Roush,et al.  Antisense Aims for a Renaissance , 1997, Science.

[14]  T. Kündig,et al.  Use of A‐type CpG oligodeoxynucleotides as an adjuvant in allergen‐specific immunotherapy in humans: a phase I/IIa clinical trial , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[15]  Fredrik Dahl,et al.  Circle-to-circle amplification for precise and sensitive DNA analysis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[16]  S. Murray,et al.  Spinal distribution and metabolism of 2′-O-(2-methoxyethyl)-modified oligonucleotides after intrathecal administration in rats , 2005, Neuroscience.

[17]  R. Griffey,et al.  Fully 2'-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. , 2005, Journal of medicinal chemistry.

[18]  Yanjie Lu,et al.  A single anti-microRNA antisense oligodeoxyribonucleotide (AMO) targeting multiple microRNAs offers an improved approach for microRNA interference , 2009, Nucleic acids research.

[19]  Derick R. Peterson,et al.  Phase II study of a TLR‐9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma , 2009, British journal of haematology.

[20]  David J. Galas,et al.  Isothermal reactions for the amplification of oligonucleotides , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Piet Herdewijn,et al.  Increased uptake of antisense oligonucleotides by delivery as double stranded complexes. , 2004, Biochemical pharmacology.

[22]  G. Uhl,et al.  Medial prefrontal cortical injections of c-fos antisense oligonucleotides transiently lower c-Fos protein and mimic amphetamine withdrawal behaviours , 1997, Neuroscience.

[23]  Shuang-yong Xu,et al.  Polymerase-Endonuclease Amplification Reaction (PEAR) for Large-Scale Enzymatic Production of Antisense Oligonucleotides , 2010, PloS one.

[24]  J. Wengel,et al.  Polymerase chain reaction and transcription using locked nucleic acid nucleotide triphosphates. , 2008, Journal of the American Chemical Society.

[25]  J. Tardif,et al.  Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy , 2012, PloS one.

[26]  S. Freier,et al.  Improved targeting of miRNA with antisense oligonucleotides , 2006, Nucleic acids research.